IFI-M · CBK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02300 // MULTI-AXIS · IFI-M

CBK Tri-Axis Dominant-Primary Series V-NP

Mentha × piperita

Peppermint

Tier VCBK Tri-Axis Dominant-Primary Series

Target Trait

2.8×

fold-change

Cooling-dominant tri-axis B+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02300

Genomic Edits

13

GC Content

45.1%

Construct Length

6,825 bp

Promoter System

Lipid nanoparticle / Ubiquitin

Expression System

Nanoparticle delivery

Host Strain

LNP-mediated

Receptor Target

TRPM8 + TAS2R38 (suppression) + CaSR

IFI Score

280

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CBK pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CBK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CBK) with cross-pathway flux managementLNP-mediated delivery of triple-axis mRNA panel for transient expression profiling

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier V CBK triple-axis construct for advanced multi-modal sensory architecture combining cooling, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$10249 · Tier V License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-MAll Modalities